{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:17Z","timestamp":1794666137889,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"HORIZON EUROPE Framework Programme","award":["101095052"],"award-info":[{"award-number":["101095052"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To determine how certolizumab pegol (CZP) dose and dose adjustments influence CZP plasma trough levels to facilitate therapeutic drug monitoring of CZP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The effect of CZP dose and dose adjustments on CZP plasma trough levels was evaluated post hoc using longitudinal data from a 52-week randomized phase III trial (RAPID 1) and its open-label extension trial. Patients with active rheumatoid arthritis treated with methotrexate for \u22656 months were randomized to CZP 200 mg, 400 mg, or placebo every other week (EOW). Patients in the extension trial were initially treated with CZP 400 mg EOW, then reduced to 200 mg EOW after \u22656 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 982 randomized patients, 846 patients entered the open-label extension trial. Median (interquartile range) plasma CZP concentrations after 12 weeks of treatment were 21.3 mg\/L (14.7, 27.7) in the 200-mg group and 38.3 mg\/L (29.2, 63.8) in the 400-mg group and increased from 18.3 (12.4, 26.5) to 43.4 (26.8, 63.3) mg\/L after dose escalation from 200 to 400 mg EOW. Following CZP dose reduction from 400 mg to 200 mg, median CZP levels decreased from 36.1 (24.9, 49.0) to 17.2 (11.5, 23.1) mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CZP plasma concentrations were influenced by both dose and dose adjustment in a predictable manner, with median plasma levels twice as high in the 400-mg group than in the 200-mg group, with a 2-fold increase after the dose increase from 200 to 400 mg. This facilitates the development of algorithms for therapeutic drug monitoring of CZP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001440","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:01:24Z","timestamp":1770008484000},"page":"481-486","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-0223","authenticated-orcid":false,"given":"Johanna E.","family":"Gehin","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf A.","family":"Klaasen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik K.","family":"Kristianslund","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Jyssum","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L.","family":"Goll","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje W.","family":"Syversen","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"R1-20261114","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-019-2009-5","article-title":"Associations between certolizumab pegol serum levels, anti-drug antibodies, and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"21","author":"Gehin","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kead525","article-title":"Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases","volume":"63","author":"Jyssum","year":"2024","journal-title":"Rheumatology (Oxf)"},{"key":"R3-20261114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","article-title":"Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine","volume":"36","author":"Gehin","year":"2022","journal-title":"BioDrugs"},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"e079830","DOI":"10.1136\/bmj-2024-079830","article-title":"Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline","volume":"387","author":"Kawano-Dourado","year":"2024","journal-title":"BMJ"},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/cts.12760","article-title":"Exposure\u2013response relationship of certolizumab pegol and achievement of low disease activity and remission in patients with rheumatoid arthritis","volume":"13","author":"Paul","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/annrheumdis-2015-208849","article-title":"High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort","volume":"76","author":"Jani","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/rheumatology\/keac564","article-title":"Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis","volume":"62","author":"Hum","year":"2023","journal-title":"Rheumatology (Oxf)"},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxf)"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1136\/annrheumdis-2013-203695","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","volume":"73","author":"Keystone","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.491","article-title":"Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease","volume":"55","author":"Wade","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"306","DOI":"10.55563\/clinexprheumatol\/nlr4r8","article-title":"The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation","volume":"38","author":"Berkhout","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:25Z","timestamp":1794664825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001440","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"2025-04-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}